Preliminary study of efficacy and safety of Pembrolizumab and Nivolumab in treatment of advanced malignant tumors
10.3760/cma.j.issn.1004-4221.2019.09.011
- VernacularTitle: 派姆单抗与纳武单抗治疗晚期恶性肿瘤疗效及安全性初步研究
- Author:
Lina HOU
1
;
Suolitiken DINA
2
;
Hua REN
3
,
4
Author Information
1. Medical abministration department, Shenzhen Hospital of Cancer Hospital, National Cancer Center, National Center for Oncology Clinical Medical Research, Chinese Academy of Medical Sciences, Peking Union Medical College, Shenzhen 518116, China
2. Department of Internal Medicine-Oncology, Shenzhen Hospital of Cancer Hospital, National Cancer Center, National Center for Oncology Clinical Medical Research, Chinese Academy of Medical Sciences, Peking Union Medical College, Shenzhen 518116, China
3. Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4. Department of Radiation Oncology, Shenzhen Hospital of Cancer Hospital, National Cancer Center, National Center for Oncology Clinical Medical Research, Chinese Academy of Medical Sciences, Peking Union Medical College, Shenzhen 518116, China
- Publication Type:Journal Article
- Keywords:
Malignant neoplasm/Immunotherapy;
Treatment outcome;
Adverse reaction
- From:
Chinese Journal of Radiation Oncology
2019;28(9):687-691
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To preliminarily compare the efficacy and safety of Pembrolizumab and Nivolumab in the treatment of advanced malignant tumors.
Methods:Clinical data of 50 patients diagnosed with advanced malignant tumors treated with Pembrolizumab and Nivolumab from January 2017 to August 2018 in our hospital were retrospectively analyzed. All patients were divided into the Pembrolizumab (n=26) and Nivolumab groups (n=24). The incidence of adverse reactions was statistically compared between two groups by using χ2 test. The survival analysis was performed by using Kaplan-Meier method.
Results:The median progression-free survival in the Pembrolizumab group was 213 d, and 146 d in the Nivolumab group (P>0.05). The incidence of aminotransferase elevation and hypothyroidism in the Nivolumab group was significantly higher than that in the Pembrolizumab group (63% vs. 23%, 12% vs. 0%, both P<0.05), whereas the incidence of oral mucositis in the Nivolumab group was 0%, significantly lower than 15% in the Pembrolizumab group (P<0.05). The median overall survival time in the Pembrolizumab group was 579 d, and 238 d in the Nivolumab group (P>0.05).
Conclusion:Clinical efficacy does not significantly differ, whereas the incidence of adverse reactions slightly differs between the Pembrolizumab and Nivolumab groups.
